Investors

Investor Relations

Landing - Corporate Profile Text

HOOKIPA Pharma Inc. is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

More events are coming soon.

News Releases

December 21, 2023
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per share Following the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock Equity investment is to advance the Gilead-partnered HIV therapeutic